Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SAMURAI trial: what clinicians have said so far
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- NCT05327686 ↗
- Recruiting
- NRG Oncology
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on SAMURAI yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SAMURAI so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma
- Interventions
- Avelumab; Axitinib; Biospecimen Collection; Bone Scan; Cabozantinib; Computed Tomography; Ipilimumab; Lenvatinib; Magnetic Resonance Imaging; Nivolumab; Pembrolizumab; Stereotactic Ablative Radiotherapy
- Arms
- Arm I (standard of care immunotherapy) · Active comparator
- Arm II (SABR, standard of care immunotherapy) · Experimental
- Enrollment
- 240 (estimated)
- Primary outcomes
- Nephrectomy and radiographic progression-free survival (nrPFS)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Feb 1, 2023
- Primary completion
- Jun 15, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05327686 · updated Oct 23, 2026